LianBio (LIANY)

OTCMKTS · Delayed Price · Currency is USD
0.1599
+0.0493 (44.58%)
At close: Jun 12, 2026
Market Cap11.96M -57.5%
Revenue (ttm)n/a
Net Income-87.98M
EPS-0.82
Shares Out 108.17M
PE Ration/a
Forward PEn/a
Dividend0.38 (344.52%)
Ex-Dividend DateJul 15, 2025
Volume317
Open0.1599
Previous Close0.1106
Day's Range0.1599 - 0.1599
52-Week Range0.0300 - 0.4394
Beta0.04
AnalystsHold
Price Target4.80 (+2,901.88%)
Earnings DateAug 13, 2026

About LianBio

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 163
Stock Exchange OTCMKTS
Ticker Symbol LIANY
Full Company Profile

Financial Performance

Financial Statements